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software, room temperature, ambient
light conditions, and probe angle may
influence the reflectance spectral values.
Thus, all reflectance spectrophotometers
should be independently validated in
appropriate and known Fitzpatrick skin
types under the environmental and
investigator conditions of assessment to
establish the mathematical-fitted equa-
tion between subjective and objective
skin phototype. Given that the same light
source was utilized throughout the stu-
dies, and reflected light spectra of
commercial color and light/dark stan-
dards were validated daily, normaliza-
tion of the reflectance spectral data with
the dark current (0% transmission) and
light source spectrum before each sub-
ject was not necessary for an accurate
skin phototype assessment. Normaliza-
tion methods may be useful, however,
when comparison between instruments,
light sources, investigators, or study
locations is desired.
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TO THE EDITOR
Although the pathogenesis of the majo-
rity of chronic idiopathic urticaria
(CIU) patients is unknown, approxi-
mately 40% of patients are proposed
to have ‘‘functional’’ IgG autoantibo-
dies against either the high-affinity IgE
receptor (FceRIa) or IgE as measured by
the basophil histamine-releasing activ-
ity (HRA) assay (Ferrer and Kaplan,
2007). This assay involves incubating
basophils from a healthy donor with a
CIU patient’s serum and measuring
histamine release. A ‘‘positive’’ result
is often judged in relation to basophil
HRA levels obtained with serum from a
non-CIU population. Some investiga-
tors have proposed that the presence of
‘‘functional’’ autoantibodies offers a
pathogenic explanation for patients’
symptoms or provides a rationale for
treatment with immunomodulatory
therapy such as cyclosporine (Sabroe
and Greaves, 2006). However, the HRA
assay, which is considered the ‘‘gold
standard’’ (Ferrer and Kaplan, 2007) for
‘‘functional’’ autoantibodies, has limita-
tions. Its performance depends on the
unique characteristics of the healthy
basophil donors (Eckman et al., 2008).
In addition, interlaboratory reproduci-
bility of this test has not been possible
to assess because of a lack of univer-
sally available standardized reagents.
An alternative line of investigation
has shown that basophils from active
CIU subjects manifest a suppressed IgE
receptor-mediated histamine degranu-
lation (Ferrer and Kaplan, 2007). We
have stratified CIU subjects into
responder (CIU R) and nonresponder
(CIU NR) functional phenotypes based
on the profile of ex vivo activation of
their basophils by an optimal concen-
tration (0.1 mgml1) of polyclonal anti-
IgE (Vonakis et al., 2007). Subjects with
o10% histamine release with anti-IgE
stimulation were classified as CIU NR,
whereas subjects with histamine release
X10% were classified as CIU R. This
basophil classification remains consis-
tent over the course of active disease
(Eckman et al., 2008). Interestingly,
increased basophil IgE-receptor-
mediated histamine release occurs in
both groups as subjects enter disease
remission (Eckman et al., 2008). Using
a previously identified immunoenzy-
mometric assay (IEMA), we observed a
similar prevalence and concentration of
IEMA-detected autoantibodies in the
CIU R, CIU NR, and non-CIU subject
groups (Eckman et al., 2008). We have
previously reported that positive HRA
presence occurs at a similar frequency
in CIU R, CIU NR, and nonatopic,
healthy (normal) subjects (Vonakis
et al., 2007). The positive HRA results
we obtained in the non-CIU subjects
have been challenged (Kaplan and
Joseph, 2007).
The purpose of this study was to
assess HRA activity in sera from CIU
and non-CIU subjects by the CU Index
test by IBT Laboratories (Lenexa, KS).
Further, we examined the relationship
of HRA activity to previously deter-
mined CIU basophil classification and
the presence of IEMA-detected autoan-
tibodies.
Following consent, whole-blood
was collected for basophil and serology
studies from subjects with a physician-
determined diagnosis of CIU (n¼ 21) or
non-CIU controls (n¼22; ages 18–65,
12 female, 10 male, 9 atopic, 13
nonatopic by history). None of the
non-CIU subjects had any known auto-
immune disease. Protocols were
approved by the Johns Hopkins Institu-
tional Review Board and the Western
Institutional Review Board and were in
adherence to the Declaration of
Helsinki Principles (Eckman et al.,
2008). Basophil functional phenotyping
studies were performed as described
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HRA, Histamine release activity; IEMA, Immunoenzymetric assay
1584 Journal of Investigative Dermatology (2009), Volume 129
JA Eckman et al.
A Commercial Test for ‘‘Autoimmune’’ Urticaria
previously (Vonakis et al., 2007). Sub-
jects with a total blood leukocyte
histamine content o5ngml1 had
extreme basopenia and were not able
to be functionally classified (CIU un-
classified). IgG anti-FceRIa and IgG
anti-IgE were measured by an immu-
noenzymometric assay as previously
described (Eckman et al., 2008). Coded
sera were sent masked to IBT Labora-
tories for analysis in their CU Index test,
which utilizes healthy donor basophils
in an HRA assay format (Altrich et al.,
2008). According to IBT Laboratories,
the CU Index cutoff is determined
based on the percentage histamine
release (of total histamine content) from
donor basophils induced by CIU sub-
ject’s serum divided by a donor-specific
‘‘cut off’’ percent histamine release,
and then this ratio is multiplied by 10.
This donor-specific ‘‘cut off’’ is deter-
mined by a statistical analysis of a
dataset obtained from a panel of nega-
tive, non-CU sera. One basophil donor
is used for all studies. A positive CU
Index result was consideredX10 based
on the HRA assay’s reported reference
range (0–50). Two-tailed Fisher’s exact
test was used for categorical analysis;
whereas a two-tailed, Mann–Whitney
U-test was used to compare the med-
ians of different groups.
CU Index values were compared to
subject classification (see Figure 1).
Positive CU Index values were seen in
both CIU and non-CIU subjects, and
therefore, positive HRA presence is not
exclusively observed in CIU subjects.
The CU Index values were higher in the
CIU group (median 17.6; n¼21) as
compared to the non-CIU group (med-
ian 6.2; n¼22, P¼0.03, Mann–Whit-
ney test). Moreover, CIU subjects (57%)
were significantly more likely to have a
positive HRA test than non-CIU sub-
jects (23%; P¼0.03, Fisher’s exact
test). In CIU subjects, the presence of
IEMA-detected IgG anti-FceRIa and/or
anti-IgE (see Figure 1a; closed symbols)
was not associated with a positive CU
Index (P¼ 0.33; Fisher’s exact test).
Among CIU basophil phenotype sub-
sets, CIU-unclassified subjects (median
17.6; n¼7) had significantly higher CU
Index values than the CIU R group
(median 6.2; n¼ 6; P¼0.01, Man-
n–Whitney test). The CIU NR subjects’
CU Index values were not significantly
different from the levels in the other CIU
groups. Between the non-CIU popula-
tions; nonatopic, non-CIU subjects
(n¼13) were more likely to have a
positive test than atopic, non-CIU sub-
jects (n¼ 9; P¼0.05, Fisher’s exact test).
The significantly higher frequency
and magnitude of CU Index values in
the CIU group as compared to non-CIU
group support the general hypothesis
that serological factors in CIU subjects
affect donor basophils differently than
non-CIU subjects. However, these data
raise questions about the clinical utility
of HRA testing in the diagnosis and
management of ‘‘autoimmune’’ CIU.
The existence of strongly positive HRA
levels in nonatopic, non-CIU patients is
similar to what we observed in our
previous studies (Vonakis et al., 2007),
and the reasons for this are not currently
understood. In addition, there was no
relationship between IEMA-detected
autoantibodies and a positive CU Index.
This lack of diagnostic specificity of
the CU Index, and thus HRA, raises
concerns about its general usefulness in
providing clarity on the disease’s patho-
genesis to CIU patients. It may be argued
that this lack of specificity may be due to
the improper selection of the basophil
donor for the HRA assay. It is not clear
from the literature how many non-CIU
subjects should be screened for low
histamine release in choosing the cor-
rect basophil donor. However, we as-
sumed that the basophil donor was
optimized for this commercial assay.
Because of the lack of consensus on the
laboratory protocols for HRA, and thus
the definition of ‘‘chronic autoimmune
urticaria’’, it cannot be said definitively
that the IBT assay used in this report
makes the distinction between autoim-
mune and idiopathic urticaria. In addi-
tion, the IBT assay that did not establish
a positive result was because of the IgG
fraction of serum. The method for
defining a positive value is different
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Figure 1. CU Index values in relation to subject grouping. (a) CU Index values for active CIU subjects
and non-CIU subjects. (b) CU Index values are subdivided by CIU functional phenotype and disease state.
Horizontal bars represent median values with 25–75% percentiles. Closed symbols are IEMA positive for
IgG anti-FceRIa and/or anti-IgE whereas open symbols are negative for both autoantibodies.
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from many other descriptions of the
HRA assay. A lack of specificity also
has been seen with the autologous
serum skin test, which is another mea-
sure of ‘‘functional’’ autoantibodies in
CIU. The autologous serum skin test is
positive in up to 37% of non-CIU
subjects (Guttman-Yassky et al., 2007).
On a limited basis, HRA-positive CIU
subjects have been reported to have
more severe disease (Sabroe et al.,
2002) and to be more likely to have
thyroid autoantibodies (Kikuchi et al.,
2003) than HRA-negative subjects. How-
ever, skin biopsies show similar patho-
logy in HRA-positive versus HRA-
negative subjects with CIU (Sabroe
et al., 1999; Ying et al., 2002). More
importantly, in making decisions about
starting immunomodulatory medication
such as cyclosporine in CIU patients,
HRA measurement is not clearly needed,
because the presence of ‘‘functional’’
autoantibodies is not correlated to
clinical response (Morgan and Khan,
2008).
At the present time, available assays
for autoimmunity are flawed and do not
consistently assist clinicians in their
understanding of CIU’s pathogenesis.
What is truly needed is a reproducible
assay to advance the specific definition
of autoimmune urticaria.
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TO THE EDITOR
Basal cell carcinoma (BCC) is the most
common cancer in humans. Very often
patients are prone to develop multiple
lesions at different body sites (Rama-
chandran et al., 1999, 2001; and cited
therein; Heitzer et al., 2007). Recently,
several studies have been performed to
determine the clonal origin of BCC in
patients with multiple lesions (Walsh
et al., 1998; Saldanha et al., 2002;
Shulman et al., 2006). For instance,
Shulman et al. (2006) performed loss
of heterozygosity (LOH) analysis and
X-chromosome inactivation studies to
determine the clonal origin of multiple
BCCs from patients exhibiting lesions at
different anatomical locations. They
reported that in all BCCs displaying
LOH, the same allele was lost in multi-
ple tumors from a given patient. Further-
more, an identical X-chromosome
inactivation pattern was noted in certain
tumors. Hence, they suggested that the
majority of BCCs in an individual might
originate from one single tumor cell
clone, independent of the anatomical
site and time of lesion occurrence.
However, van Steensel and Frank
(2006) questioned the theory of mono-
clonality of multiple BCCs. They stated
that it is important to sequence the
PTCH gene to prove monoclonality of
multiple BCCs because PTCH mutations
are a hallmark of BCCs. If identical
PTCH mutations are present in distinct
BCCs at different anatomical locations
from individual patients with multiple
lesions, it would indicate monoclonal-
ity. If not, then it would suggest that
each tumor arises independently from a
distinct initiated (progenitor) cell.
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